References
- Nutt JG, Muenter MD, Melton LJ 3d, et al. Epidemiology of dystonia in Rochester, Minnesota. Adv Neurol 1988; 50: 361–5
- Fahn S, Bressman SB, Marsden CD. Classification of dystonia. Adv Neurol 1998; 78: 1–10
- Bressman SB, de Leon D, Raymond D, et al. Clinical-genetic spectrum of primary dystonia. Adv Neurol 1998; 78: 79–91
- Greene P, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 1988; 3(l): 46–60
- Fahn S. Systemic therapy of dystonia. Can J Neurol Sci 1987; 14(3 Suppl): 528–32
- Jankovic J. Medical therapy and botulinum toxin in dystonia. Adv Neurol 1998; 78: 169–83
- Hyland K, Arnold LA, Trugman JM. Defects of biopterin metabolism and biogenic amine biosynthesis: clinical, diagnostic, and therapeutic aspects. Adv Neurol 1998; 78: 301–8
- Furukawa Y, Kish SJ. Dopa-responsive dystonia: recent advances and remaining issues to be addressed. Mov Disord 1999; 14(5): 709–15
- Greene P, Shale H, Fahn S. Experience with high doses of anticholinergic and other drugs in the treatment of torsion dystonia. Adv Neurol 1988; 50: 547–56
- Penn RD, Gianino JM, York MM. Intrathecal baclofen for motor disorders. Mov Disord 1995; 10(5): 675–7
- Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48(2): 358–62
- Adler CH. Botulinum toxin treatment of movement disorders. In: Gilman S, Goldstein GW, Waxman SG, eds. Neurobase. (Book on CD-ROM). 3d ed. San Diego: Arbor Publishing, 1999
- Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994
- Lang AE. Surgical treatment of dystonia. Adv Neurol 1998; 78: 185–98